Diagnomics uses the chip and Global Screening Array (GSA) manufactured by Illumina to provide microarray analysis service. Our GSA is comprised of a highly optimized, universal genome-wide backbone that can generate clinical research variants and track sample content. Our experiment yields an accurate data set that is certified by Illumina.

 Microarray allows us to quantify disease-related mutations and examine alterations in gene expressions. Through our system, we can help provide more accurate diagnoses with individualized treatment planning. Examining gene expressions allows us to monitor cellular response to treatments, enhance treatment plans, and develop new methods for disease detections from alterations in gene expressions.